News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
GuruFocus Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have collectively reported a beneficial ownership stake of 7.06% in Hemab Therapeutics Holdings, Inc. (COAG). This ownership comprises 3,298,236 shares of common stock, acquired solely for investment purposes on behalf of their respective funds. …
Analysts have provided new ratings for several healthcare companies. Truist Financial maintained a Buy rating on Genmab (GMAB), while Deutsche Bank maintained a Hold rating on Definitive Healthcare Corp (DH). Additionally, Deutsche Bank downgraded Atai Beckley N.V. (ATAI) to Hold.
Touchstone Global Investments Pty Ltd has reported a 5.2% passive stake in Chemomab Therapeutics Ltd. (CMMB), holding 377,814 American Depositary Shares (ADSs). This disclosure, filed on a Schedule 13G, indicates that Touchstone Global has sole voting and dispositive power over these shares, with each …
HC Wainwright has lowered its FY2026 earnings per share estimate for Hemab Therapeutics to a loss of $3.19 per share, down from $3.12, while reaffirming a "Buy" rating and a $60 price target. The revision follows Hemab's recent quarterly EPS of $(0.80), which missed …
Gladstone Land Corp reported a net loss of $8.5 million and negative adjusted FFO in Q2 2026, despite strong almond and pistachio markets. The company highlighted improved liquidity, proactive portfolio management, and potential revenue from water leases and solar projects. Challenges include continued weakness …
Genmab A/S has filed an updated Articles of Association with the SEC, documenting a nominal share capital of DKK 62,377,844 and extending the board's authority to issue shares, warrants, and convertible debt through 2029 and 2030. This follows a recent capital increase from employee …
Earnings Call Insights: Gladstone Land Corporation (LAND) Q2 2026 MANAGEMENT VIEW * "We currently own about 98,000 acres across 142 farms and about 56,000 acre feet of water" (Founder, Chairman, CEO & President David Gladstone), and "we didn't have any acquisitions or dispositions this …
Hemab Therapeutics (NASDAQ:COAG) shares recently hit a new 52-week high of $54.19 following an analyst upgrade from HC Wainwright, which raised its price target to $60 and maintained a Buy rating. The company holds a "Moderate Buy" consensus from analysts with an average price …
Genmab A/S has filed a Form 6-K report with the SEC, furnishing its Articles of Association. This report is incorporated by reference into six of Genmab's existing Form S-8 registration statements, indicating a change to their incorporated content. The filing was accepted by SEC …
Capital International Investors has disclosed a 7.7% beneficial ownership stake in Hemab Therapeutics Holdings, Inc. (COAG), as per a Schedule 13G filing. The firm beneficially owns 3,603,876 shares of common stock, representing 7.7% of the 46,705,410 shares outstanding, and holds sole voting and dispositive …
Gladstone Land Corporation reported a wider-than-expected Q2 2026 net loss of $0.32 per share, missing analyst estimates of $0.26 per share, despite revenue exceeding forecasts at $12.69 million. The agricultural REIT saw improved adjusted FFO due to stronger crop pricing and cash receipts, particularly …
This article provides a rundown of top Wall Street analyst research calls for Wednesday, August 12, 2026, featuring upgrades, downgrades, and new initiations for various companies like Hilton Worldwide, The Gap, Intuitive Surgical, Merck, and Novo Nordisk. It also covers pre-market stock futures, bond …
Analysts have issued a "Moderate Buy" consensus recommendation for Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG), with an average 12-month price target of $49.60. The company recently reported a quarterly loss per share of $0.80, missing consensus estimates, but insiders have been actively purchasing shares. Hemab …
This article from Investing.com announces the filing of a Form 8K by Hemab Therapeutics Holdings for August 11. The brief piece includes the stock market category but provides no further details on the content of the Form 8K.
Genmab A/S (NASDAQ:GMAB) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $39.50, suggesting upside from its current $30.85 share price. The company recently surpassed quarterly earnings estimates, reporting $0.54 EPS against a $0.37 consensus and …
H.C. Wainwright has reaffirmed its Buy rating on Hemab Therapeutics Holdings (COAG.US) and increased its target price to $60. This indicates a positive outlook from the firm regarding the company's future performance and stock valuation.
Gladstone Land Corporation reported its financial results for the second quarter ended June 30, 2026, noting a net loss of $8.5 million but an improvement in AFFO per share compared to the prior year. The company highlighted a shift in revenue recognition to primarily …
Gladstone Land Corporation reported a net loss of $8.46 million for the second quarter of 2026, with a net loss attributable to common stockholders reaching $13.52 million. These figures were disclosed in their Form 10-Q filing with the SEC on August 11, 2026. The …
This article provides a brief snapshot of Gladstone's Q2 earnings. It appears to be a placeholder or an article that did not fully load, as no specific financial details or further text are present. The content is limited to the headline and publication time.
Gladstone Land (NASDAQ:LAND) reported quarterly EPS of ($0.32), missing analyst estimates by $0.06, though revenue of $12.69 million exceeded expectations. The stock is trading near its one-year low, and the company announced a monthly dividend of $0.0467 per share, yielding approximately 6.8%. Analyst sentiment …
Gladstone Land Corporation reported a net loss of $8.5 million in Q2 2026, alongside increased cash flow from operations of $19.9 million, a 404.7% year-over-year rise. The company experienced a shift towards participation-based rents on "Repositioned Farms" and significantly reduced its total indebtedness by …
Genmab A/S has announced a capital increase of 24,592 shares, resulting from the exercise of employee warrants, which will generate approximately DKK 37.9 million for the company. This increase represents about 0.04% of Genmab's total share capital, which will now stand at DKK 62,377,844. …
Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup positive 55.7%HC Wainwright has increased its price target for Hemab Therapeutics (NASDAQ:COAG) to $60.00 from $52.00, maintaining a "buy" rating, which suggests a potential upside of 16.91%. The company has a consensus "Moderate Buy" rating from analysts, with shares recently trading up 2.9% despite missing …
Hemab Therapeutics (COAG) reported a Q2 net loss of $0.80 per share, which is wider than the FactSet estimate of a $0.56 loss. The company is a clinical-stage biotechnology firm focused on developing therapies for blood coagulation disorders, with lead assets in Phase 1/2 …
Hemab Therapeutics reported a Q2 2026 net loss of $24.2 million but maintains a strong cash position of $457.5 million, expected to fund operations into 2029 following $317.2 million from its IPO. The company reiterated key clinical milestones for sutacimig, HMB-002, and the newly …
Agomab Therapeutics (AGMB) has announced a special and extraordinary general shareholders' meeting for September 11, 2026, in Antwerp, Belgium. The company plans to propose the appointment of Marino Garcia and Dr. Naimish Patel as non-executive directors for four-year terms, subject to shareholder approval. Additionally, …
Erik Otto, an investor in Chemomab Therapeutics Ltd. (CMMB), has filed an amended Schedule 13G, disclosing beneficial ownership of 90,000 American Depository Shares (ADSs), which represents 1.2% of the company's outstanding ADSs. Each ADS represents twenty ordinary shares. Otto holds sole voting and dispositive …
Goldman Sachs has reaffirmed its Buy rating for Genmab A/S (0MGB) with a price target of $33.50, following a report by Rajan Sharma. UBS also issued a Buy rating for Genmab, though Morgan Stanley maintained a Hold rating on the same day. Genmab's current …
Search by ticker symbol or company name and select a result to open its chart.